Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
IJI-Iranian Journal of Immunology. 2015; 12 (4): 302-310
in English | IMEMR | ID: emr-181366

ABSTRACT

Background: Ruptured cerebral aneurysms [ICAs] are the most common non-traumaticcause of subarachnoid hemorrhage [SAH] that is associated with life threateningcomplications such as Vasospasm, Infarction, and Hydrocephalus [HCP]. The activeparticipation of macrophage/monocyte-mediated inflammatory response in thepathogenesis of cerebral aneurysm as labeled with Monocyte ChemoattractantProtein-1[MCP-1] is suggested


Objective: To measure the serum level of MCP-1 in rupturedCAs in different time intervals


Methods: We measured the serum levels of MCP-1 inSAH patients who had CAs and compared it with that of MCP-1 in two control groups:including patients with SAH without CAs, and the normal population of blood donors.We also measured the MCP-1 levels in patients with CAs one week afterward toevaluate the effect of treatment. Serum level of MCP-1 was measured by a commercial ELISA assay


Results: Mean serum MCP-1 level in patients with SAH and CAs was188.2168 Pg/ml and 331.3982 Pg/ml in the normal population. There was nostatistically significant difference between serum levels of MCP-1 on the first[mean=188.2168 Pg/ml] and 7th days after SAH onset [mean=171.8450 Pg/ml][p=0.739]. Serum level of MCP-1 increased significantly as Glasgow Coma Scaledecreased [p=0.078] and Hunt and Hess score increased [p=0.089]


Conclusion: Ourresults did not show an increasing MCP-1 serum level in patients with aneurysmalSAH. There was a relationship between poor clinical grade and MCP-1 levels inpatients with CAs. MCP-1 may be a local inflammatory marker for cerebral aneurysmswithout systemic manifestation

SELECTION OF CITATIONS
SEARCH DETAIL